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Background: Examination of bronchoalveolar lavage, induced sputum, and peripheral blood
indicate that cysteinyl leukotriene receptor blockers decrease inflammatory cells in asthma
but these do not examine airway tissue per se.
Objectives: Our objective was to determine the effect of montelukast, a leukotriene receptor
antagonist, on airway tissue inflammatory cells by direct bronchoscopic examination of the
bronchial mucosa.
Methods: Adult subjects with mild asthma (pre-bronchodilator FEV1  70% predicted; PC20 of
4 mg/mL) were given 10 mg/day oral montelukast (NZ 38) or placebo (NZ 37) for 6 weeks.
Bronchial mucosal eosinophils and mast cells were identified and counted.
Results: Change from baseline in numbers of biopsy EG2þ (‘‘activated’’) eosinophils was the
primary endpoint; numbers of total (chromotrope 2Rþ) eosinophils and (tryptaseþ) mast cells
were secondary. Unexpectedly, there were many patients with zero EG2þ eosinophils at base-
line. There was a within-group decrease in EG2þ cells, from 13.54 cells/mm (at baseline) to
0.79 cells/mm at 6 weeks in the montelukast group (LS mean change; 95% confidence inter-
valZ 13.59 [25.45, 1.74] cells/mm; P < 0.05), a change not observed in the placebo
group (1.17 [13.26, 10.91] cells/mm; NS). The zero-inflated Poisson statistical model
demonstrated that montelukast significantly reduced post-treatment EG2þ cells by 80%
compared with placebo (95% CI [70.6e86.8%]; P < 0.0001). The data for total eosinophils
showed similar changes. The reduction in mast cell numbers was 12% (95% CI [7.9, 16.0];
P < 0.0001).gy, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK. Tel.: þ44 0 207 351 8422; fax: þ44
l.ac.uk (P.K. Jeffery).
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996 C.F. Ramsay et al.Conclusion: Direct examination of airway tissue confirms that montelukast decreases the
number of eosinophils and mast cells in asthma.
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Asthma is a chronic inflammatory disorder of the airways
associated with increased numbers of mucosal eosinophils,
mast cells and T lymphocytes.1,2 These can be reduced, at
least in part, by treatment with either inhaled or oral
corticosteroids.3e6. However, there is evidence that corti-
costeroids do not treat all of the component inflammatory
mediators of asthma. Among these, lipid-derived media-
tors, the cysteinyl leukotrienes (cysLTs) LTC4, LTD4 and
LTE4, have potent biologic effects, including recruitment of
eosinophils to the bronchial mucosa,7 increased vascular
permeability, mucus hypersecretion, hyperresponsiveness
and bronchoconstriction.8e11 In addition, cysLTs have the
capacity in animal models of asthma to induce chronic
remodelling of the airway wall.12
There are distinct approaches to reducing the actions of
cysLTs: inhibition of biosynthesis (e.g., inhibitors of 5-lip-
oxygenase (5-LO) and 5-LO-activating protein) or blockade
of cysLT receptors using leukotriene receptor antagonists
(LTRAs).13 CysLT receptors have been cloned and charac-
terised and identified in lung tissue.14,15 Moreover, a recent
study of endobronchial biopsies has demonstrated the
presence of a number of distinct cysLT receptor1-bearing
cells in the airway mucosa of normal healthy humans and
shown that their numbers are increased in stable asthma
and further increased in patients experiencing severe
exacerbations of asthma.16 Thus, targeting cysLT
receptor1-bearing cells for the purpose of attenuating the
many actions of cysLTs is a valid approach to anti-inflam-
matory therapy in asthma. In support of this, drugs that
block either the production or site of action of the cysteinyl
leukotrienes have shown clinical benefit in the treatment of
chronic asthma in both adults and children.17,18 There are
indications from studies of bronchoalveolar lavage
(BAL),19,20 induced sputum21 and peripheral blood17,22 that
cysteinyl leukotriene receptor blockers decrease the
numbers of inflammatory cells in asthma, particularly
eosinophils. For example, the LTRA montelukast reduces
sputum eosinophils both in the asthmatic adult and
child.21,23 Additionally, montelukast reduces eosinophil
products and LT concentrations in nasal washes taken from
children with asthma.24 Pre-treatment with zafirlukast
significantly reduces the allergen-induced increase of BAL
lymphocytes and basophils seen at 48 h after segmental
allergen challenge.20 The only interventional study with an
LTRA examining human bronchial tissue was that of Naka-
mura et al.,25 who reported that pranlukast given for
4 weeks reduced the numbers of eosinophils, mast cells and
T-lymphocytes.
The present multicentre study set out to determine
whether treatment with the potent and specific LTRA
montelukast in a broader population of mild asthmatic
patients would reduce the numbers of eosinophils and mast
cells detected in bronchial biopsies of individuals with mild
persistent asthma.Methods
Subjects
Our entry criteria were based on GINA guidelines and a physi-
cian assessment of a clinical diagnosis of asthma backed up by
a histamine challenge test confirming bronchial hyperreac-
tivity. Patients between the ages of 18 and 45 years with
a clinical history ofmild asthmaof1 year duration and apre-
bronchodilator FEV1 of 70% predicted (with b2-agonist
treatment withheld for 6 h) participated in the study. The
70% cut off was designed to exclude patients whose asthma
was of a severity that it would be clinically inappropriate not
to start them on inhaled steroids. Our subjects could be
classified either as ‘‘intermittent’’ or ‘‘mild persistent’’
depending upon their reported symptoms or documented PEF
variability. Subjects’ symptoms were controlled by ‘‘as
required’’ short-acting b2-agonist use. None had received
regular treatment with inhaled, oral or injected steroids or
inhaled cromolyn, nedocromil or ketotifen3 months (or any
single dose for 6 weeks), nor taken oral theophylline within
2 weeks or a long-acting b2-agonist within 1 week of starting
the study. All subjects were current non-smokers, had not
smoked for at least a year prior to the study, and had a history
equal to or less than 10 pack-years. Patients were in good
health and had no other significant disease or medication
requirements before or during the study.Study design
This was a randomised, double-blind, placebo-controlled,
parallel group study performed at five clinical centres
worldwide (UK, Finland, Chile, Peru and Guatemala). The
protocol was approved by the local institutional review
boards and in keeping with the Declaration of Helsinki. All
patients gave written informed consent to participate in
the study before any study-related procedures were per-
formed. Patients underwent a pre-study screening visit
where a full clinical assessment including baseline spirom-
etry, chest X-ray, electrocardiogram, skin-prick testing to
common allergens and histamine challenge testing were
performed. Qualified patients were randomly assigned to
receive either montelukast or placebo according to
a computer-generated, randomised allocation schedule
with a blocking factor of four. Patients subsequently
underwent two bronchoscopies: the first prior to and the
second after 6 weeks of treatment with either montelukast
or placebo. All bronchoscopies, biopsy procedures, and
specimen processing were performed according to
a protocol standardised across the study centres. The
primary endpoint was the change from baseline in the
number of EG2þ (‘‘activated’’) eosinophils per unit area of
bronchial biopsy in patients who had received montelukast
for 6 weeks compared with those who had received
placebo. Secondary endpoints comprised the number of
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cells (AA1 tryptase) in biopsy specimens.
Physiologic measurements
All spirometric measurements were made at 9 am  2 h on
a spirometer calibrated weekly and conforming to accepted
American Thoracic Society criteria. Patients demonstrated
airway hyperresponsiveness to histamine with a PC20 of
4 mg/mL. Histamine challenge testing was performed
with a Devilbiss 646 nebuliser calibrated to an output of
0.13 mL/min. Doubling concentrations of histamine starting
with 0.03 mg/mL were administered for 2 min at 5-min
intervals until a decrease in FEV1 of 20% was achieved.
The histamine PC20 was interpolated from the last two data
points on a plot of the log concentration of histamine
against percent decrease in FEV1.
Bronchoscopy
All bronchoscopies, biopsy procedures, and specimen pro-
cessingwere performedaccording to a protocol standardised
across the study centres. Prior to each bronchoscopy at
10 am  2 h, all patients received 2.5 mg nebulised salbu-
tamol, 600 mg intravenous atropine, 4e10 mg intravenous
midazolam and topical xylocaine spray to the nose and
throat. During the procedure, patients received topical
lignocaine (4% and 2%) to the vocal cords and airways and also
nasal oxygen supplementation at 2e4 L/min. The bronchos-
copies were performed by one of two designated persons at
each site. At each bronchoscopy, six endobronchial biopsies
were taken from the sub-carinae of the right lung. The
biopsies were taken with fenestrated cup biopsy forceps
(Pentax KW2411S) that were replaced at least every four
bronchoscopies. A note was made of the sub-carinae from
which the biopsies were taken, and at the second bron-
choscopy, the same airway generations but different micro-
anatomical sites of the right lung were sampled.
Biopsy handling
Three biopsies were fixed in 10% buffered formaldehyde for
between 1 and 4 days, when they were processed to
paraffin wax. Five-micrometre-thick sections were stained
with an antibody directed against EG2 (to identify ‘‘acti-
vated’’ eosinophils) or chromotrope (2R) (a marker for total
eosinophils), and AA1 tryptase (mast cells). Chromotrope-
2Rþ and immuno-positive cells were counted in an area of
subepithelium to a pre-defined depth of 100 mm that
excluded mucus-secreting glands and bronchial smooth
muscle, and their numbers were expressed per millimetre
length reticular basement membrane (RBM). Although the
study was not designed nor powered to examine changes in
RBM thickness, this was recorded in the biopsies of 28
montelukast-treated and 26 placebo-treated subjects.
Total thickness of the RBM was assessed by a single observer
by light microscopy using haematoxylin and eosin-stained
tissue sections and image analysis. Repeat measurements
were taken at 20-mm intervals and, where adequate tissue
was available, the geometric mean of 30 measurements
was taken for each subject, as previously recommended.26Statistical methods
Efficacy analyses were performed by an external consultant
statistician (D. Wang); the sponsor statistician (A. Swern)
confirmed the efficacy analyses and performed all addi-
tional analyses. A per-protocol analysis was performed for
the analyses of the primary end point and other airway
inflammatory cells in bronchial biopsies due to the scien-
tific question being addressed. The intention-to-treat (all-
patients-treated) principle, i.e., inclusion of all patients
with a baseline and a post-baseline measurement, was also
applied as a corroborative analysis for the bronchial biopsy
end points. Change from baseline for the primary endpoint
(EG2þ cells) and for the two secondary endpoints, chro-
motrope-positive cells and tryptase-positive mast cells, was
analysed first using the a priori agreed ANOVA model that
included factors for centre and treatment. If the 95%
confidence interval for the mean change from baseline for
a particular treatment group did not contain the value
zero, then the within-group change is statistically signifi-
cant (P < 0.05). After an initial review of the data when still
blinded, it was initially thought that no transformation of
these data would be required because of the robust nature
of the ANOVA method. However, a review of the unblinded
data demonstrated a significant number of samples with
zero counts at both baseline and post-treatment, and it was
agreed to conduct post-hoc analyses more appropriate to
the distribution of these data. Models based on the normal
distribution, such as the linear regression model, cannot be
used even after a log-transformation of cell count data
because of the excess zero counts. The Poisson regression
model, ordinarily used for count data, is also not appro-
priate since each of the post-treatment means for each of
the three post-treatment counts is much smaller than the
corresponding variance, and a property of the Poisson
distribution is that the mean and variance are equal. A
more appropriate model for the post-treatment counts is
the zero-inflated Poisson (ZIP) model, which incorporates
an estimate for the excess of zeros over those allowed by
the Poisson model.27e29 The baseline cell count is also
included as a covariate in the ZIP model analysis to adjust
for the baseline difference in the cell counts.
The study was designed such that a sample size of
NZ 24 in each group yielded 80% power to detect (at an
aZ 0.05, two-tailed test) a 50% reduction from baseline in
the number of EG2þ cells present in bronchial biopsy in the
montelukast group compared with placebo. This statement
was based on data from previous studies30,31 where the
coefficient of variation was 86% (standard deviation [SD] for
the log-transformed variable was 75%). Compared with
placebo, changes to RBM thickness as the result of mon-
telukast treatment were assessed by Mann Whitney U test.
Results
Disposition of subjects
Of the 88 patients randomised to the study [43 M, 45 P], 75
patients [85.2%; 38 M, 37 P] had evaluable biopsies and
were included in the per-protocol dataset. One patient in
the placebo group was discontinued from the study due to
998 C.F. Ramsay et al.airway inflammation and pneumonia. Data from three
patients taking montelukast and five patients taking
placebo were invalid or were missing biopsies at either
baseline or post-treatment. Data from one patient taking
montelukast and one taking placebo were eliminated
because their PC20 values were not in the protocol-specified
range. Data from one patient taking montelukast and one
taking placebo were removed from the per-protocol anal-
ysis dataset because the patients had not taken the study
drug on one of two days before the biopsy (Fig. 1). Table 1
summarises baseline characteristics for the remaining 75
per-protocol patients. There were no clinically meaningful
differences between the montelukast and placebo groups.
Counts of inflammatory cells
Against expectation, eosinophils were found variably and
infrequently and, when present, often clustered together.
In contrast, mast cells were always present, frequent and
evenly distributed throughout the tissue. The data for cell
counts per unit area are summarised in Figs. 2ae4a and
demonstrate the high proportion of sections in which EG2þ
(48%) and chromotropeþ (24%) cells were undetected at
baseline. There was no suggestion of an association
between the presence or absence of biopsy eosinophils and
a subject history of allergy. Individual patient data for each
cell type are shown in Figs. 2be4b.
EG2-positive cells
Using the ANOVA statistical model, there was a significant
within-group decrease in the mean EG2þ cell count, from
13.54 cells/mm (at baseline) to 0.79 cells/mm in theRandomi
(88)
Montelukast
Randomized
(43)
Montelukast
Completed
study
(43)Discontinued (4)
invalid or missing biopsy data
(3)
biopsy not in correct range for
PC20 hyperresponsiveness (1)
Discontinued (1)
eliminated for not
having taken study drug
both days prior to
biopsy
Montelukast
Valid biopsy
data
(39)
Montelukast
Per protocol
dataset
(38)
Figure 1 Subjecmontelukast group (P < 0.05) with an LS mean change and
associated 95% confidence interval of 13.59 [25.45,
1.74] cells/mm. By comparison, the change in the
placebo group, from 6.70 to 6.34 cells/mm, was not
statistically significant, with an LS mean change of 1.17
(95% CI [13.26, 10.91]) cells/mm. The difference
between the montelukast and placebo groups in the
change from baseline in EG2þ cells was not statistically
significant (PZ 0.13). In contrast, the ZIP model, more
appropriate to the observed non-normal distribution of
these data, shows that compared with placebo and after
controlling for the excess zeros in EG2þ cell counts at
baseline and post-treatment, montelukast reduced the
post-treatment EG2þ counts by 80.3% (95% CI [70.6%,
86.8%]) (Table 2).
Chromotrope-positive cells
Using the ANOVA statistical model, there was a significant
(P < 0.05) within-group decrease after montelukast treat-
ment in the mean chromotropeþ cell count from 3.89 cells/
mm (at baseline) to 1.13 cells/mm; the LS mean change
was 2.65 (95% CI [4.69, 0.61]) cells/mm. By compar-
ison, the placebo group showed a decrease from 2.80 to
2.17 cells/mm, which was not statistically significant; with
the LS mean change of 0.42 (95% CI [2.50, 1.66]) cells/
mm. The difference between montelukast treatment and
placebo in the change from baseline in chromotropeþ cells
was not statistically significant (PZ 0.115). However, after
applying the ZIP model, which took into account the excess
zeroes in the distribution, the average reduction in
chromotropeþ cells was 54.4% (95% CI [28.0, 71.1];
P < 0.001).zed
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Discontinued (1)
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Table 1 Patient baseline characteristics.
Characteristic Montelukast Placebo Total
N % N % N %
Sex
Male 19 50.0 13 35.1 32 42.7
Female 19 50.0 24 64.9 43 57.3
History of allergic conjunctivitis
Yes 13 34.2 11 30.6 24 32.4
No 25 65.8 25 69.4 50 67.6
History of allergic rhinitis
Yes 10 26.3 13 35.1 23 30.7
No 28 73.7 24 64.9 50 69.3
History of allergic conjunctivitis or
allergic rhinitis
Yes 29 76.3 25 67.6 54 72.0
No 9 23.7 12 32.4 21 28.0
Positive skin test to at least
one allergen
Yes 28 75.7 30 83.3 58 79.5
No 9 24.3 6 16.7 15 20.6
NZ 38 NZ 37 NZ 75
Mean (SD) Median Mean (SD) Median Mean (SD) Median
Age (years) 29.2 (7.7) 27.0 30.6 (7.9) 27.0 29.9 (7.8) 27.0
Weight (kg) 67.9 (10.6) 65.8 69.4 (13.4) 65.8 68.6 (12.0) 65.8
Height (cm) 167.5 (8.6) 167.0 166.5 (9.5) 166.0 167.0 (9.0) 166.0
Duration of asthma (years) 16.1 (10.7) 16.2 14.6 (10.0) 16.1 15.4 (10.4) 16.2
Smoking history (pack-years) 0.9 (2.2) 0 1.6 (5.6) 0 1.2 (4.3) 0
FEV1 (percent predicted) 86.7 (15.8) 85.0 89.3 (13.6) 87.9 88.0 (14.7) 87.2
FEV1 (percent reversibility) 11.4 (8.2) 10.3 11.3 (11.1) 8.2 11.3 (9.7) 9.4
Blood eosinophils (103/mL) 0.4 (0.3) 0.2 0.3 (0.2) 0.3 0.3 (0.2) 0.3
Histamine PC20 (mg/mL) 0.5 (0.7) 0.2 0.4 (0.5) 0.2 0.4 (0.6) 0.2
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Figure 2 EG2-positive eosinophils. Graphical representation
of the data for EG2-positive eosinophil counts per unit area
(arrowsZ median values).
Anti-inflammatory effects of montelukast 999Tryptase-positive mast cells
By ANOVA, there was a significant (P < 0.05) within-group
decrease in the mean tryptase-positive mast cell count
from 164.64 cells/mm (at baseline) to 98.83 cells/mm in
the montelukast group; the LS mean change was 68.00
(95% CI [103.91, 32.08]) cells/mm. The placebo group
showed a within-group decrease from 129.57 to
101.35 cells/mm, which was not statistically significant;
the LS mean change was 28.59 (95% CI [65.21,
8.03]) cells/mm. The difference between the placebo and
montelukast groups in the change from baseline in mast
cells was not statistically significant (PZ 0.114). After
taking into account the excess zeros in the distribution, the
average reduction in mast cell numbers was 12.1% (95% CI
[7.9, 16.0]; P < 0.0001).
There was no significant difference between the mon-
telukast and placebo groups in epithelial RBM thickness.
The median change was þ0.6 mm (95% CI [0.3, 1.7]) for
montelukast and 0.5 (95% CI [1.2, 0.2]) for placebo.
Discussion
The present study shows that 6 weeks of treatment with
montelukast was associated with a significant within-group
reduction of EG2þ cells, from 13 cells/mm at baseline to
fewer than 1 cell/mm at the end of treatment, whereas thechange within the placebo group was not statistically
significant. Application of the pre-specified ANOVA analysis
demonstrated that the difference between montelukast
and placebo in change of EG2þ cells was not statistically
significant (PZ 0.13). However, there were a significant
number of zero values in the data set, in excess of those
anticipated. In order to take account of the excess of zero
values in these non-normally distributed data, application
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Figure 3 Chromotrope-positive eosinophils. Graphical
representation of the data for chromotrope-positive eosinophil
counts per unit area (arrowsZ median values).
Table 2 Results from the zero-inflated Poisson (ZIP)
model analysis.
Cell type Treatment
effect on
incidence
rate
P-value 95% confidence
interval
Lower
limit
Upper
limit
Post-EG2 0.1966 <0.0001 0.1312 0.2944
Post-mast 0.8795 <0.0001 0.8396 0.9213
Post-chromotrope 0.4558 0.0010 0.2887 0.7198
Percent reduction expressed as (1.00  incidence rate)/
1.00)  100.
1000 C.F. Ramsay et al.of the ZIP statistical model demonstrated that, compared
with placebo, montelukast significantly reduced the
number of post-treatment EG2þ cells by approximately 80%
(P < 0.0001). The data for total eosinophils showed
a similar pattern of change. In addition, there was a 12%
reduction in mast cell numbers with montelukast treat-
ment, also significant by ZIP analysis.
The pro-inflammatory nature of LTs and anti-inflamma-
tory effects of LTRAs have been reviewed.9e11 More recent
studies of exhaled breath condensate in asthmatic patients
treated with corticosteroids demonstrate that, in many,
suppression of inflammation by corticosteroids is incom-
plete. In these patients, the LTRA montelukast, given for
4 weeks, reduces cysLT as well as LTB4 concentrations and
improves symptoms.32 Montelukast reduces the number of
sputum eosinophils in asthma,21 reduces eosinophil cationic
protein (ECP) and LT concentrations in nasal washes,
and improves lung function in children with persistent
asthma.18,24 Moreover, patientswithmild asthma challenged
with allergen respond with an early-phase (0e3 h) and
subsequent late-phase (3e8 h) reduction in lung function:
both the early-phase and, importantly, the late-phase asth-
matic responses are significantly attenuated by pre-Placebo (N = 37) Montelukast (N = 38)
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Figure 4 Tryptase-positive mast cells. Graphical represen-
tation of the data for tryptase-positive mast cell counts per
unit area (arrowsZ median values).treatment with montelukast.33 This effect of montelukast is
not attributable to direct bronchodilation, as baseline
measures of lung function were unchanged: it likely reflects
the suppression of smooth muscle constriction induced by
the cysLTs released during the inflammatory response.
There may also be chronic effects of LTs that affect the
processes of airway smooth proliferation and remodelling.
LTD4 potentiates epidermal growth factor-induced
increases in myocyte DNA synthesis and cell number, and
this effect can be abolished by LTRAs.34 In addition, mon-
telukast can attenuate the increase of allergen challenge-
induced myofibroblast formation and the in vitro migration
of airway smooth muscle that occurs in response to
platelet-derived growth factor; both are thought to play
a role in the process of airway wall remodeling.35e37
In a placebo-controlled endobronchial biopsy study of
asthmatics treated with the LTRA pranlukast for 4 weeks,
immunohistologic analyses revealed that LTRA administra-
tion reduced the numbers of eosinophils, mast cells and T-
cells in addition to improving patients’ asthma symptoms.25
In a double-blind parallel comparison of fluticasone and
montelukast in bronchial biopsies obtained from 36 mild
atopic asthmatics treated for 8 weeks, both treatments
showed a similar non-significant trend to reduced numbers
of tissue eosinophils, whereas the significant reduction of
mast cells seen with fluticasone was not achieved following
montelukast.38
Thus, on balance the evidence of the present study in
combination with other published data suggests that
treatment with the cysteinyl LTRA montelukast results in
anti-inflammatory effects in patients with mild asthma.
Moreover, these data in humans are supported by studies of
animal models of asthma in which montelukast has been
shown to block or reverse sub-acute allergen-induced
eosinophilic inflammation and structural changes that
include increases of smooth muscle mass and subepithelial
fibrosis.39 In respect of the last-mentioned, the lack of
effect on the RBM thickness in the present human study is
likely a reflection of the relatively short duration of treat-
ment. It has been shown previously that although anti-
inflammatory treatment with inhaled corticosteroids
reduces inflammation within the first 3 months, reduction
of RBM thickness in humans requires at least 1 to 2 years of
treatment.5,6 Our study was neither designed nor powered
to examine the effects of intervention on the remodelling
process. Studies of longer duration will be needed to assess
the effect of montelukast on airway RBM thickening and the
Anti-inflammatory effects of montelukast 1001capacity of montelukast to further reduce the eosinophilia
when added to optimal steroid therapy.
Variability of eosinophils
At the time the study was designed and conducted (1995) it
was commonly thought that inflammation was a cardinal
feature of all asthma and that eosinophils would be present
in the bronchial biopsies of all asthmatics. However, we
observed a more erratic inter- and intra-biopsy distribution
of eosinophils than expected, which challenged the
assumption of broad eosinophilic inflammation in asthma.
Thus, we were forced to reconsider the most appropriate
analyses for these data. The observations of eosinophil
scarcity in subsets of asthmatics have since been repeated
and today there is formalised acceptance of asthma
phenotypes, in part, based on the predominant pattern of
inflammatory cells. One of these is characterised by
eosinophil paucity and neutrophil predominance.40,41
Analyses made prior to and since the present study have
shown that there is large variation in counts of inflamma-
tory cells between patients, between airway generations,
between biopsies, between tissue sections, around the
internal circumference of the airway, and with time.
Richmond et al.42 looked at variability within biopsies,
lobes and patients in 12 mild asthmatic subjects biopsied
1 month apart, noting large intra-subject variations with
time that outweighed intra-subject bronchoscopy differ-
ences. This and a previous study by Bentley and
colleagues43 showed that using three or more step sections
from the same biopsy gave relatively small coefficients of
variability for a range of inflammatory cells. However, the
study by Sullivan and co-workers26 found a high variance in
bronchial biopsy inflammatory cell counts, noting that they
were not normally distributed and that the cumulative
weighted mean did not become stable until 5e10 mm of
tissue underlying the RBM had been included. They calcu-
lated that the median number of sections required from
a biopsy before the cumulative weighted mean was within
20% of the final result was two sections, but that the 75th
percentile was six sections. Few studies have included such
amounts of tissue in their analyses, including the present
one. Since the present study was conducted, Gamble and
colleagues44 have shown in subjects with chronic obstruc-
tive pulmonary disease (COPD) that the largest contribution
to variability is time (39%), followed by airway generation
(23%), biopsy (2.5%), zone within a tissue section (1.4%) and
section (0.4%). In another study, the variability around the
internal circumference of the airway of a CD8þ inflamma-
tory cell (less variable than the eosinophil) was consider-
able, and the authors concluded that in order to achieve
a representative count and to maximise statistical power to
detect differences between study populations, biopsy
tissue including a minimum of 5 mm of RBM should be
examined.45 These observations of variability provide
a possible explanation for the zero values for eosinophils
that we observed in the present study. In addition, it must
be recognised that the finding of a large number of zero
values might represent a true biologic finding, given that
most of the patients with zero values at baseline had zero
values after treatment in either group. This finding could be
consistent with the hypothesis that the eosinophil might beplaying a supportive role rather than a primary role or that
it is important in some patients and not in others.46
In addition, we noted that, unlike several of the cell
types examined in the aforementioned studies, the eosin-
ophils in our biopsies were not evenly distributed
throughout the tissue (in contrast to mast cells), but rather
were usually present as clusters, with large areas of tissue
devoid of them. Such a sporadic distribution, together with
the mild nature of the asthma in our subjects and an
analysis of a single tissue section and biopsy from each
subject likely all contribute to the excess of zero values
seen in our primary endpoint. Yet despite these contribu-
tions to variability, there was still a significant reduction of
eosinophils and mast cells afforded by montelukast treat-
ment when the statistical model appropriate to the excess
of zero values was applied. Further, this study highlights
the critical importance of collaboration, standardisation,
quality control, and the application of methodology
appropriate and tailored to the study design and the
question being asked.47
Conclusion
Whilst there was a significant within-group reduction, the
a priori agreed ANOVA did not demonstrate that mon-
telukast given over 6 weeks significantly altered the change
from baseline in the numbers of EG2þ bronchial mucosal
eosinophils in comparison with placebo. However, the
appropriateness of applying the pre-specified ANOVA anal-
ysis to the number of zero values observed after unblinding
was questioned. Post-hoc analysis using the zero-inflated
Poisson (ZIP) statistical model was more appropriate to
these data as it controlled for the excess of zero values in
the non-normally distributed baseline and post-treatment
cell counts. Applying the ZIP model demonstrated that
montelukast treatment significantly reduced the number of
EG2þ (‘‘activated’’) eosinophils, chromotropeþ (total)
eosinophils and mast cells.
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